Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA) Please click the li...
#CSuite Neill Blue Appointed as ViON CFO; Tom Frana Comments – Neill Blue Appointed as ViON CFO; Tom Frana Comments GovConWireFull coverage http://bit.ly/2ADSnqN
— Muzaffaruddin Alvi (@Muzaffar1969) December 8, 2017
https://platform.twitter.com/widgets.js
#CSuite ELEMENTIS PLC – Company Secretary Change – ELEMENTIS PLC – Company Secretary Change Yahoo Finance UKFull coverage http://bit.ly/2B260mr
— Muzaffaruddin Alvi (@Muzaffar1969) December 8, 2017
https://platform.twitter.com/widgets.js
#CSuite NPRO: HAAVARD RØNNING APPOINTED NEW CFO IN NORWEGIAN PROPERTY – NPRO: HAAVARD RØNNING APPOINTED NEW CFO IN NORWEGIAN PROPERTY NB HerardFull coverage http://bit.ly/2BGHKDe
— Muzaffaruddin Alvi (@Muzaffar1969) December 7, 2017
https://platform.twitter.com/widgets.js
What exactly is corporate #governance? Why is it so important? Find out on 12 July at our training course https://t.co/QEDTtrVvUh #corpgov
— ICSA (@ICSA_News) June 17, 2017
//platform.twitter.com/widgets.js
from http://twitter.com/ICSA_News
June 17, 2017 at 02:50PM
via IFTTT
http://ift.tt/2nvvNwD
June 12, 2017 at 02:53PM
from
http://ift.tt/2npyb4K
June 12, 2017 at 02:53PM
from
http://ift.tt/2oUiSVn
June 12, 2017 at 02:53PM
from
http://ift.tt/2oVoHhG
June 12, 2017 at 02:53PM
from
A month has gone by since the last earnings report for Kite Pharma, Inc. KITE. Shares have added about 6.3% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock’s next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted of late, let’s take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Kite Pharma Posts Q1 Loss
Kite Pharma reported a loss of $1.74 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.68 per share as well as the year-ago loss of $0.90 per share.
First-quarter revenues came in at $9.84 million, below the Zacks Consensus Estimate of $15.30 million but up almost 92% from the year-ago period. In the quarter, the company recognized $5.5 million under the Amgen deal and $4.2 million under the Daiichi Sankyo agreement.
While Kite Pharma’s research and development expenses shot up 91.5% from the year-ago period to $65.9 million in the reported quarter, general and administrative expenses were $35.8 million, up 114.5% from the year-ago period.
Kite Pharma ended the year with $804.0 million in cash and marketable securities compared with $414 million at the end of the fourth quarter last year. The increase was due to $409.7 million received from a follow-on offering of common stock and $50 million in upfront payment from Daiichi Sankyo.
2017 Guidance
Net cash burn in 2017 is expected to be between $325 million and $340 million.
Operating expenses are expected to be between $490 million and $515 million in 2017.
The company does not expect to generate any product revenues from axicabtagene ciloleucel in 2017.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
Kite Pharma, Inc. Price and Consensus
VGM Scores
At this time, Kite’s stock has a poor Growth Score of ‘F’, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of ‘F’ on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of ‘F’. If you aren’t focused on one strategy, this score is the one you should be interested in.
Our style scores indicate investors will probably be better served looking elsewhere.
Outlook
Notably, the stock has a Zacks Rank #3 (Hold). We expect in-line returns from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kite Pharma, Inc. (KITE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
June 12, 2017 at 02:50PM
from Zacks Equity Research
http://ift.tt/2secERQ
June 12, 2017 at 02:52PM
from PTI
A month has gone by since the last earnings report for j2 Global, Inc. JCOM. Shares have lost about 3.4% in that time frame, underperforming the market.
Will the recent negative trend continue leading up to the stock’s next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted of late, let’s take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
First Quarter Earnings
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
j2 Global, Inc. Price and Consensus
VGM Scores
At this time, j2 Global’s stock has a nice Growth Score of ‘B’, though it is lagging a lot on the momentum front with an ‘F’. However, the stock was allocated a grade of ‘B’ on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of ‘B’. If you aren’t focused on one strategy, this score is the one you should be interested in.
Zacks’ style scores indicate that the company’s stock is suitable for value and growth investors.
Outlook
Notably, the stock has a Zacks Rank #3 (Hold). We expect in-line returns from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
j2 Global, Inc. (JCOM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
June 12, 2017 at 02:50PM
from Zacks Equity Research
http://ift.tt/eA8V8J
Cristiano Ronaldo and LeBron James lead the list of Forbes magazine’s richest athletes in the world for 2017. There is a significant gap between the top three (Ronaldo, James, and Messi) and the rest of the list. The Real Madrid star Ronaldo is estimated to have earned a total of $93 million, with Cleveland Cavaliers …
June 08, 2017 at 02:43PM
from Dr. Amarendra Bhushan Dhiraj
http://ift.tt/2s8Hbk8
June 05, 2017 at 02:44PM
from
http://ift.tt/2s8qd5A
June 05, 2017 at 02:44PM
from
http://ift.tt/eA8V8J
Buy Vascon Engineers Ltd. at a price target of Rs 63.0 and a stoploss at Rs 48.3 from entry point.
June 05, 2017 at 02:44PM
from
http://ift.tt/eA8V8J
Edelweiss Financial Services has a reduce call on Castrol India Ltd. in the long term at a price target of Rs 424
June 05, 2017 at 02:44PM
from
http://ift.tt/eA8V8J
Edelweiss Financial Services has a long-term positive on Hindustan Unilever Ltd and maintains a hold at a price target of Rs 1,106.
June 05, 2017 at 02:44PM
from
http://ift.tt/2s8Hcoc
June 05, 2017 at 02:44PM
from
http://ift.tt/2mdOm8C
June 01, 2017 at 02:42PM
from
The UK manufacturing sector growth moderated in May from a three-year high, survey results from IHS Markit and the Chartered Institute of Procurement & Supply showed Thursday.
The factory Purchasing Managers’ Index fell to 56.7 in May from 57.3 in April. Nonetheless, the score was above the expected level of 56.5 and signaled an improvement in conditions for the tenth consecutive month.
Manufacturing production and new orders both expanded at above survey average rates in May.
The ongoing expansion of the manufacturing sector had a positive impact on both business sentiment and job creation.
Rates of inflation in input costs and output charges remained elevated in May, despite easing further from recent highs.
“While not quite hitting the heights of April’s rebound in activity, the manufacturing sector didn’t disappoint with a sustained rise in purchasing activity, output and new orders, optimism at a 20-month high, and storming ahead unfazed by the looming election,” Duncan Brock, director of customer relationships at the Chartered Institute of Procurement & Supply, said.
The material has been provided by InstaForex Company – www.instaforex.com
June 01, 2017 at 02:44PM
from
